The occurrence of cancer in nine recipients — two of which involved evidence that a viral delivery tool integrated into ...

Today, a brief rundown of news involving Eli Lilly and Alnylam Pharmaceuticals, as well as updates from Servier, Ultragenyx, Boehringer Ingelheim and ANI Pharmaceuticals that you may have missed.

The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of ...

J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment ...

Wall Street analysts are already resetting projections for Rasonque — but company executives cautioned that it’s too early to ...

The startup is built around technology it claims can help get after known, but undruggable cancer targets and design ...

The startup is working on a medicine one of its investors claimed could have a broader reach than other approved drugs for a ...

The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a ...

The drug’s third-quarter sales numbers came in well above consensus estimates, widening Novo’s early edge over Eli Lilly in the latest battleground for weight loss medicines. The Wegovy pill ...

Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have ...

On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall ...

The health policy think tank urged seniors to shop carefully for prescription drug coverage during Medicare open enrollment, given skyrocketing premiums and wide variance in costs between plans.